Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.51 |
| ▸ | ITGAL | P20701 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | GRN | P28799 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444839 | 1.00 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| Hydrochloric Acid SCHEMBL4862500 | 0.99 | ALDH1A1 (0.57) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL30051464 | 0.91 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL6976264 | 0.91 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL9272265 | 0.91 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL7357698 | 0.91 | ALDH1A1 (0.60) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL8667829 | 0.90 | ALDH1A1 (0.56) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL9230708 | 0.89 | KDM4C (0.59) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL4891798 | 0.84 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTKDM4CHDAC8 | |
| SCHEMBL7339828 | 0.83 | GRN (0.70) | ALDH1A1MAPTRAB9ASMN1; SMN2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006134612-A1 | A PROCESS FOR THE PREPARATION OF SAQUINAVIR USING NOVEL INTERMEDIATE | HETERO DRUGS LIMITED (IN) | 2006-12-21 | — | — | WO | claimed |
| EP-0847994-B1 | Process for the preparation of mixed anhydrides | HOFFMANN LA ROCHE (CH) | 2003-04-09 | — | — | EP | claimed |
| US-5914404-A | Process for the preparation of quinargine | HOFFMANN-LA ROCHE INC. (US) | 1999-06-22 | — | — | US | claimed |
| EP-0611774-B1 | Production of amides and peptides without racemization in the presence of catalytic amounts of a N-hydroxy-compound | HOFFMANN LA ROCHE (CH) | 1999-05-26 | — | — | EP | claimed |
| EP-0847994-A1 | Process for the preparation of mixed anhydrides | F. HOFFMANN-LA ROCHE AG (CH) | 1998-06-17 | — | — | EP | claimed |
| EP-0827507-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-03-11 | — | — | EP | claimed |
| EP-0823424-A1 | Process for the preparation of quinargine | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-11 | — | — | EP | claimed |
| WO-1996031527-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1996-10-10 | — | — | WO | claimed |
| US-5536816-A | Process for producing amides using catalytic amounts of an N-hydroxy compound | HOFFMANN-LA ROCHE INC. (US) | 1996-07-16 | — | — | US | claimed |
| EP-0611774-A1 | Production of amides and peptides without racemization in the presence of catalytic amounts of a N-hydroxy-compound | F. HOFFMANN-LA ROCHE AG (CH) | 1994-08-24 | — | — | EP | claimed |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3192794-A1 | SUSTAINED HIV PROTEASE INHIBITOR | Shionogi & Co., Ltd. (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9096576-B2 | Compounds and methods for treatment of systemic lupus erythematosus | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140309255-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2014-10-16 | — | — | US | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| WO-1993001166-A1 | 4-AMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES | SANDOZ LTD. (CH) | 1993-01-21 | — | — | WO | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0432694-A2 | Aminoalcohols | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-19 | — | — | EP | disclosed |
| EP-0432695-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | ALDH1A1 4195/4885GAA 1507/4885MAPT 4683/4885 |
| US-20140309255-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, DNASE1L3, SNRPD2 | ALDH1A1 3364/4885GAA 1281/4885MAPT 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.